FDA Grants Priority Review for Genzyme ’s Cerdelga™ (eliglustat), an Investigational Oral Therapy for Gaucher Disease
Isis Pharmaceuticals Reports Fifth Positive Phase 2 Data Set for ISIS-APOCIII Rx Showing Significant Reductions in Triglyceride and ApoC-III Levels
Sanofi to Make EUR1 Billion-EUR2 Billion Worth of Acquisitions a Year -Report
Isis Pharmaceuticals Reports Positive Phase 1 Data Demonstrating ISIS-APO(a) Rx Produces Significant Reductions in Lp(a) Levels
Research and Markets: Market Research - Relapsing Multiple Sclerosis (RMS) - Pipeline Review, H2 2013
Research and Markets: Australia Orthopedic Biomaterial Market Outlook, 2005 - 2018
InVivo Therapeutics Founders Take on Parkinson’s Disease with PixarBio Corporation
The broad stock runup in the first half of 2013 was a boon to ClearBridge Aggressive Growth, and comanager Evan Bauman says that the fund is well-positioned for the market going forward.
Focusing on stocks with the most visible cash flows has been a winning strategy, and this screen can find them.